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Abstract: 
Design of potential drug-like candidates for cancer is of interest in recent years. We used 60 compounds which are known to have the potential to down regulate 
Nuclear Factor kappaB (NFκB) for this study. The compounds were assessed for Lipinski's RO5 and ADMET properties. Allixin, anethole, capsaicin, linearol and 
syringic acid satisfied both Lipinski's RO5 and ADMET properties. These compounds showed strong molecular interaction with receptor GPCR55 indicating they 
have ability to block GPCR55. Thus, their role in anticellular proliferation and induction of apoptosis is implied.  
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Background: 
Cancer is now a serious global health problem. Cancer is caused by a complex, 
poorly understood interplay of genetic, molecular and environmental factors 
[1]. Some conventional systems such as surgery, chemotherapy, radiation 
therapy, immunotherapy, monoclonal antibody therapy or other methods are 
being used for cancer treatment. Most of the agents are known to be mutagenic 
and or carcinogenic, and are highly toxic for normal cells [2]. Due to the toxic 
and adverse side effects caused by synthetic medicine, herbal medicines are 
alternatives to treatment [3]. Plant extracts and natural compounds purified 
from plants have been used by humans for many centuries for the treatment of 
a variety of inflammation-related diseases, including cancer [4]. Computer 
aided drug design have gained popularity and have become an integral part of 
the industrial and academic research for drug development [5]. Transforming 
ligands into active compounds with non-promiscuous-binding behaviour, 
known as hits; and then refining them into a structure or series of structures 
with relevant biological and drug-like activity, known as leads;  are the key 
starting points for drug discovery programs [6-7]. Tumorogenesis is a multistep 
process that can be activated by any of various environmental carcinogens 
(such as cigarette smoke, industrial emissions, gasoline vapors), inflammatory 
agents (such as tumor necrosis factor (TNF) and H2O2), and tumor promoters 
(such as phorbol esters and okadaic acid). These carcinogens are known to 
modulate the transcription factors (e.g., NF-kB, AP-1, STAT3), anti-apoptotic 
proteins (e.g., Akt, Bcl-2, Bcl-XL), proapoptotic proteins (e.g., caspases, 
PARP), protein kinases (e.g., IKK, EGFR, HER2, JNK, MAPK), cell cycle 
proteins (e.g., cyclins, cyclin-dependent kinases), cell adhesion molecules, 
COX-2 and growth factor signalling pathways [8]. Many ligands acting via 
GPCRs, including thrombin, bombesin, radykinin, substance P, endothelin, 
serotonin, acetylcholine, gastrin, prostaglandin F2alpha, and lysophosphatidic 
acid are known to elicit a mitogenic response in a variety of cell types [9]. We 
used compounds which have potential to downregulate Nuclear Factor kappaB 
as reviewed elsewhere [4] and show their ability to induce apoptosis and inhibit 
cell proliferation by blocking G-protein coupled receptor 55 (GPCR55) using 
computer aided screening studies. 
 
Methodology: 
Polyphenolic phytocompounds:  
We used 60 compounds which are known to have the potential to down 
regulate Nuclear Factor kappaB (NFκB) for this study [4]. These compounds 
were already established as possible inhibitors of the NFκB pathway on animal 
and cancer cell line models. 
 
T-cell receptor structure:  
We used the T-cell receptor structure with PDB ID: 2X70 from protein 
databank (PDB) for this study.  
 
Software and tools: 
We used ACD/Chemsketch version 12 [10] to draw molecular structures and 
calculate chemical properties. The ADMET (Absorbtion, Distribution, BIOINFORMATION  open access 
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Excretion, Metabolism, Toxicology) properties were calculated for the 
phytocompounds using Accord for excel an Accelry’s product [11]. The 
docking module in Discovery Studio, an Accelrys Software Inc (2.1) is used for 
docking studies [12]. 
 
 
Figure 1: Drug-Receptor interaction. The docked complexes are (A) allixin; 
(B) anethole; (C) capsaicin; (D) linearol;  (E) syringic acid; (F) Zoladex 
(Reference drug) with G-protein coupled receptor 55.  
 
Results: 
Figure 1 shows the interaction of GPCR55 domain with allixin, anethole, 
capsaicin, linearol, syringic acid and Zoladex. The results of drug-receptor 
interaction for compounds are given in Table 1 (see Supplementary 
material). These compounds were selected from 12 out of the 36 compounds 
in the original list of 60 compounds which satisfied Lipinski's RO5 and 
ADMET properties. 
 
Discussion: 
The aim in drug design is the identification of novel small molecular scaffold 
exhibiting high binding affinity and selectivity for the target together with a 
reasonable absorption, distribution, metabolism, excretion and toxicity 
(ADMET) profile [13]. The simplest ADME-concerned filter is the Lipinski 
RO5  [14-15]. We used the 60 compounds which are known to have the 
potential to down regulate Nuclear Factor kappaB (NFκB) for this study [4]. It 
has been suggested that the predictable reactions typically are dose-related. 
Hence, there is a need to predict the toxic nature of these compounds [16]. 
Thus, these compounds were tested for Lipinski RO5 and ADMET properties. 
Analysis suggests that 36 of the 60 compounds satisfied Lipinski RO5 and 
ADMET properties analysis.  
  
The computer aided toxicity screening was performed using Accord for Excel 
[11] and thus, 12 compounds with hepatotoxicity value ‘0’ indicating non-toxic 
effect. Thus, these 12 compounds have satisfied both the Lipinski’s rule of five 
and ADMET, achieving the status of ‘oral drug-likeness’ and are chosen for 
docking against the receptor GPCR55. Zoladex (low logP and high molecular 
weight), a commonly used reference molecule violated criteria for 
consideration as oral drug-likeness in Lipinski RO5 and ADMET analysis. 
Thus, the need to design compounds satisfying Lipinski RO5 and ADMET 
properties is important. A good docking interaction implies the prediction of 
ligand confirmation and orientation within targeted binding site and their lower 
interactions energies [17-18]. Docking results (Figure 1; Table 1) show that 5 
compounds (allixin, anethole, capsaicin, linearol and syringic acid) have good 
molecular interactions with the receptor GPCR55.  
  
Zoladex is being used alone or in combination with tamoxifen as a cytotoxic 
chemotherapy in patients with hormone receptor-positive tumours and is found 
to be effective when used after adjuvant chemotherapy [19]. It is also widely 
used in the treatment of advanced prostate cancer as well as for breast cancer 
[20]. However, it should be noted that Zoladex violates some of the molecular 
properties. Nonetheless, polyphenolic phytocompounds namely allixin, 
anethole, capsaicin, linearol and syringic acid satisfy both Lipinski’s rule of 
five and ADMET properties. They also have produced good results for 
molecular interaction with the receptor GPCR55 in docking models. Thus, the 
role of these compounds in inhibiting GPCR55 activity is implied for 
consideration in cancer related illness.  
 
Conclusion: 
The compounds allixin, anethole, capsaicin, linearol and syringic acid satisfied 
Lipinski’s RO5 and ADMET properties. The interactions of these compounds 
with GPCR55 were found to be strong in docking models. Thus, their potential 
ability to block GPCR55 is implied for consideration in drug design and 
development for cancer associated illness.  
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Supplementary material: 
 
Table 1: Results of Drug-Receptor Interactions 
Compounds  Docking pose     Docking Scores  Receptor- ligand Hydrogen bonds 
Absolute 
energy 
Libdock score/ 
No. of Hot spots 
Total no. of  H 
bonds/ 
No. of contacts 
Amino 
acid 
Position Atom  in 
amino 
acid 
Atom in 
Ligand 
Bond 
length 
Allixin 37.052  106.496/ 
"4.59,8.01,6.95,A,57,5-2.39,-
7.81,10.95,P,59,90.81,7.21,10.15,A,67,15
" 
1/ 
6 
GLU 192  OE2  H34  2.17653 
Anethole 27.785  90.911/ 
"5.01,- 6.41,15.55,A,88,1 8.01,-
5.61,19.15,A,97,5 6.81,-
3.81,18.35,A,96,9" 
0/ 
11 
-  - - - - 
Capsaicin 35.705  141.365/ 
"-4.19,- 13.01,5.35,A,48,7-1.79,-
8.21,9.95,A,66,181.81,-  
6.41,7.35,A,60,22" 
2/ 
5 
ASP 
ASP 
189 
189 
OD1 
OD2 
H46 
H46 
1.84857 
2.38704 
Linearol 57.072  101.382/ 
"-4.59,-  8.01,6.95,A,57,1  
-4.99,-14.01,4.35,A,38,8 
0.21,-16.01,5.15,A,46,17" 
0/ 
9 
-  - - - - 
Syringic 
acid 
34.445 68.893/ 
"1.81,-6.41,7.35,A,60,1 -4.59,- 
8.01,6.95,A,57,11 0.41,-
7.61,11.75,P,63,14” 
2/ 
6 
ALA 
TRP 
190 
215 
O 
O 
H24 
H20 
2.28496 
2.11200 
Zoladex 64.012  146.95/ 
"-4.19,-13.01,5.35,A,48,3 -4.59,-
8.01,6.95,A,57,34 -1.79,-
8.21,9.95,A,66,39" 
6/ 
6 
ALA 
GLY 
GLY 
ASN 
THR 
GLU 
195 
193 
193 
143 
147 
39 
HN 
HN 
HN 
HD22 
O 
OE1 
O33 
O33 
O7 
O29 
H73 
H59 
1.69827 
1.96936 
1.64495 
2.12107 
2.22932 
1.87838 
 
 